These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27826027)

  • 21. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial.
    Kang HJ; Loftus S; Taylor A; DiCristina C; Green S; Zwaan CM
    Lancet Oncol; 2015 Apr; 16(4):385-94. PubMed ID: 25770814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
    J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
    Choi MR; Jiles C; Seibel NL
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):e268-71. PubMed ID: 20736848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis.
    Yarboro CH; Wesley R; Amantea MA; Klippel JH; Pucino F
    Ann Pharmacother; 1996; 30(7-8):752-5. PubMed ID: 8826554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ex-Vivo percutaneous absorption of enrofloxacin: Comparison of LMOG organogel vs. pentravan cream.
    Kirilov P; Tran VH; Ducrotté-Tassel A; Salvi JP; Perrot S; Haftek M; Boulieu R; Pirot F
    Int J Pharm; 2016 Feb; 498(1-2):170-7. PubMed ID: 26688043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types.
    Aapro MS; Schmoll HJ; Jahn F; Carides AD; Webb RT
    Cancer Treat Rev; 2013 Feb; 39(1):113-7. PubMed ID: 23062719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
    Ng WL; Della-Fiorentina SA
    Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
    Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
    J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
    Ito Y; Karayama M; Inui N; Kuroishi S; Nakano H; Nakamura Y; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Hayakawa H; Suda T; Chida K
    Lung Cancer; 2014 Jun; 84(3):259-64. PubMed ID: 24746177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical practice guidelines on antiemetics in oncology.
    Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.
    Osorio-Sanchez JA; Karapetis C; Koczwara B
    Intern Med J; 2007 Apr; 37(4):247-50. PubMed ID: 17388865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
    Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
    Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
    Bodge M; Shillingburg A; Paul S; Biondo L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1111-3. PubMed ID: 24357337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.